Atezolizumab

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4629 publications

Correction: Modeling brain metastases in cost effectiveness analysis of atezolizumab for extensive stage small cell lung cancer.

Correction: Modeling brain metastases in cost effectiveness analysis of atezolizumab for extensive stage small cell lung cancer.

Journal: Scientific reports
Published: June 16, 2026

Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Clinical Models: MEKiAUTO.

Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Clinical Models: MEKiAUTO.

Journal: JCO precision oncology
Published: June 12, 2026

Targeted immunotherapy and tumor immunogenicity in liver transplant recipients: A study on lenvatinib and PD-L1 inhibition.

Targeted immunotherapy and tumor immunogenicity in liver transplant recipients: A study on lenvatinib and PD-L1 inhibition.

Journal: Pakistan journal of pharmaceutical sciences
Published: June 09, 2026

Treatments for metastatic non-small cell lung cancer: a pathways pilot with systematic review, evidence synthesis and economic model.

Treatments for metastatic non-small cell lung cancer: a pathways pilot with systematic review, evidence synthesis and economic model.

Journal: Health technology assessment (Winchester, England)
Published: June 05, 2026

Neuroimmune Crosstalk: Peripheral Nervous System Disorders After Immune Checkpoint Inhibitors.

Neuroimmune Crosstalk: Peripheral Nervous System Disorders After Immune Checkpoint Inhibitors.

Journal: Journal of clinical neuromuscular disease
Published: June 02, 2026

Phase Ib/II trial to evaluate the safety and efficacy of atezolizumab and bevacizumab as adjuvant therapy following carbon-ion radiotherapy in hepatocellular carcinoma (VANGUARD): study protocol.

Phase Ib/II trial to evaluate the safety and efficacy of atezolizumab and bevacizumab as adjuvant therapy following carbon-ion radiotherapy in hepatocellular carcinoma (VANGUARD): study protocol.

Journal: BMJ open
Published: June 02, 2026

Rethinking Progression in Hepatocellular Carcinoma: Is Oligoprogression a Window for Local Ablation?

Rethinking Progression in Hepatocellular Carcinoma: Is Oligoprogression a Window for Local Ablation?

Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: May 31, 2026

Addition of Intravesical Recombinant BCG to Perioperative Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase 2 Trial SAKK 06/19.

Addition of Intravesical Recombinant BCG to Perioperative Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase 2 Trial SAKK 06/19.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 29, 2026

Comment on "The Advanced Lung Cancer Inflammation Index as a Prognostic Indicator in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy".

Comment on "The Advanced Lung Cancer Inflammation Index as a Prognostic Indicator in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy".

Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: May 25, 2026

Immune checkpoint inhibitors and chemotherapy versus chemotherapy for early triple-negative breast cancer.

Immune checkpoint inhibitors and chemotherapy versus chemotherapy for early triple-negative breast cancer.

Journal: The Cochrane database of systematic reviews
Published: May 21, 2026

Atezolizumab-Associated Autoimmune Diabetes Presenting as Diabetic Ketoacidosis in a Woman With Hepatocellular Carcinoma: A Case Report.

Atezolizumab-Associated Autoimmune Diabetes Presenting as Diabetic Ketoacidosis in a Woman With Hepatocellular Carcinoma: A Case Report.

Journal: Cureus
Published: May 14, 2026

Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10).

Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10).

Journal: BMJ open
Published: May 13, 2026
Showing 1-12 of 4,629

Last Updated: 06/30/2026